fda glp-1 compounding enforcement november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Managing Compounded GLP-1 Medications: A

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance and impaired ?-cell function

With 90 servings per container (1 capsule per serving) and no established daily values for the active ingredients, the focus remains on delivering a simple, effective, and well-balanced probiotic solution for daily use

If youve ever heard someone say, Just eat less and move more, you know exactly what Im talking about

NexLife vs Ro, Hims vs Henry Meds, Wegovy vs Zepbound, and more.

Arthritis includes a range of conditions that affect the joints, from inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis to more common conditions like osteoarthritis